These findings are noteworthy because many approved biological therapeutics lose efficacy due to issues with immunogenicity and alternatives must be sought as follows: (i) Since the 1970’s, L-asparaginase derived from Escherichia coli has been considered the first-line therapy to deplete serum asparagine levels in acute lymphoblastic leukemia patients. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.